Saturday 17 October 2026
Export ORIC’s income statement to Excel — free account
Oric Pharmaceuticals, Inc.
ORIC Healthcare Biotechnology
In the quarter to June 2026, EPS grew 19.2% and free cash flow fell 3.42%, each against the same quarter a year earlier.
12.35
0.42
−3.29%
Follow ORIC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(39.73%) | (41.27%) | (42.57%) | (39.80%) | |
| (36.90%) | (37.91%) | (39.79%) | (37.35%) | ||
ROIC |
(77.24%) | (86.88%) | (70.11%) | (83.77%) | |
Return on Tangible Assets |
(48.66%) | (47.87%) | (49.24%) | (55.00%) | |
Free Cash Flow per Share |
(1.18) | (1.27) | (1.05) | (1.04) | |
Free Cash Flow |
(117.24) | (111.68) | (111.20) | (112.26) | |
Capital Expenditures |
(0.70) | (0.71) | (0.33) | (0.62) | |
| Other line items | |||||
Cash ROIC |
(16.89%) | (16.77%) | (15.94%) | (17.38%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.86 | 0.86 | 0.82 | 0.80 | |
Depreciation/Fixed assets |
(0.97) | (0.45) | (0.03) | 0.34 | |
Capex/Depreciation |
0.28 | 0.66 | 4.81 | (0.81) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.18) | (1.26) | (1.05) | (1.03) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates